Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Shr-A1921 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Shr-A1921 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Shr-A2009 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A2009 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Shr-A2102 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A2102 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
Sorafenib Advanced Colorectal Carcinoma	Fudan University	P2	CCC (53)
Sorafenib Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
TAMOXIFEN Pancreatic Neoplasm	Fudan University	P2	CCC (53)
TAURURSODIOL Hepatocellular Carcinoma	Fudan University	P2	CCC (53)
Theophylline Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Tislelizumab Clear Cell Renal Carcinoma	Fudan University	P2	CCC (53)
Tislelizumab Perioperative Immunotherapy	Fudan University	P2	CCC (53)
Tislelizumab Pulmonary Metastasis	Fudan University	P2	CCC (53)
Toripalimab Acral Lentiginous Melanoma	Fudan University	P2	CCC (53)
Toripalimab Cutaneous Melanoma	Fudan University	P2	CCC (53)
tqb2102 Breast Neoplasm	Fudan University	P2	CCC (53)
tqb2102 Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
tqb2102 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
tqb2102 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
tqb2868 Breast Neoplasm	Fudan University	P2	CCC (53)
tqb2868 Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)
tqb2868 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
tqb2868 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
TRASTUZUMAB Hormone Receptor Negative Tumor	Fudan University	P2	CCC (53)

Showing 376 to 400 of 615 assets

PreviousPage 16 of 25Next